TCMD — Tactile Systems Technology, Inc.

TCMD Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $75.3 million, up 23% year-over-year.
• Lymphedema Revenue: $62.2 million, a 23% increase.
• Airway Clearance Revenue: $13.0 million, a 22% increase.
• Gross Margin: 76.5%, up 250 basis points from the previous year.
• Adjusted EBITDA: $3.7 million, compared to an adjusted EBITDA loss of $300,000 in Q1 2025.
• Net Loss: $1.8 million, or $0.08 per diluted share, down from a loss of $3.0 million or $0.13 per diluted share in the prior year.
• Cash Position: Approximately $75 million, down from $83.4 million at the end of 2025.

2. Strategic Updates and Business Highlights

• Strategic Priorities: Focus on improving access to care, expanding treatment options, and enhancing lifetime patient value.
• Acquisition of Lymphotech: Integrated into operations; expected to enhance R&D capabilities and contribute to revenue through government grants.
• Prior Authorization Implementation: Successfully accelerated the launch of a prior authorization module for Medicare, aimed at improving operational efficiency.
• Product Innovations: Received FDA clearance for the next-generation AffloVest, expected to launch in time for the 2026-2027 winter respiratory season.
• Market Dynamics: Strong growth in both lymphedema and airway clearance segments, with a notable increase in Medicare sales (40% year-over-year).

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Updated to $360 million to $368 million, reflecting a 9% to 12% year-over-year growth.
• Adjusted EBITDA Expectation: Projected at $49 million to $51 million for the year.
• Gross Margin Outlook: Expected to remain between 76% to 77%.
• Operating Expenses: Anticipated increase of 10% to 12% year-over-year due to ongoing investments and acquisition-related costs.

4. Bad News, Challenges, or Points of Concern

• Prior Authorization Transition: Early variability in approval rates among Medicare Administrative Contractors (MACs) could impact revenue predictability.
• Operating Expenses: Increased operational costs due to investments in technology and integration of Lymphotech may pressure margins.
• Market Dynamics: Potential delays in order processing as the new prior authorization requirements settle could affect sales cadence in the near term.

5. Notable Q&A Insights

• Clarification on Sales Dynamics: Management clarified that recent sales acceleration was not a pull-forward from Q2 but rather an effort to benefit patients before the new prior authorization rules took effect.
• Lymphotech Contribution: Expected to enhance R&D capabilities but not materially impact revenue in the short term; future contributions will depend on successful integration and development of new products.
• Impact of New Pharmaceuticals: Introduction of a new bronchiectasis drug is raising awareness but does not replace the need for airway clearance therapies, maintaining the relevance of TCMD's products.
• Sales Team Productivity: Transitioning from capacity building to productivity, with expectations for revenue per representative to improve as the year progresses.

This summary encapsulates the key takeaways from TCMD's Q1 2026 earnings call, highlighting both the positive developments and potential challenges the company faces moving forward.